The interaction between nanoparticles and proteins is a central problem in the nano-bio-fields. However, it is still a great challenge to characterize the specific interaction between nanoparticles and proteins in structural details. Using the Goldbodies, the artificial antibodies created by grafting complementary-determining regions (CDRs) of natural antibodies onto gold nanoparticles, as the models, we manage to identify the key residues of the CDR peptides on gold nanoparticles for the specific interactions by alanine scanning mutagenesis. Each and every residue of the CDR peptides on two Goldbodies (which specifically bind with hen egg white lysozyme and epidermal growth factor receptor, respectively) is mutated to alanine one by one, generating a total of 18 single-mutants of the two Goldbodies. Experimental results reveal that the key residues of the CDR peptides for the specific interactions between the two Goldbodies and the corresponding antigens are exactly the same as those in the natural antibodies, thus proving that the correct conformations of the CDRs of natural antibodies have been successfully reconstructed on AuNPs. This is the first residue-resolution structural illustration for the specific interaction between a designed nanoparticle and a protein.
Many efforts have been made to develop inhibitors of MDM2 as potential drugs for cancer therapy. In this work, we use our previous developed conformational engineering technique to stabilize the binding conformation of the p53 transcription activation domain (TAD) peptide on gold nanoparticles (AuNPs), and create an AuNP‐based anti‐MDM2 artificial antibody, denoted as anti‐MDM2 Goldbody, that specifically binds MDM2. Though the free TAD peptide is unstructured, circular dichroism (CD) spectra confirm that its α‐helical conformation in the original p53 protein is restored on the anti‐MDM2 Goldbody, and surface plasmon resonance (SPR) experiments confirm that there is strong specific interaction between the anti‐MDM2 Goldbody and MDM2, demonstrating the anti‐MDM2 Goldbody as a potential inhibitor of MDM2. This work demonstrates that the conformational engineering technique is not limited to the antigen‐antibody systems, but can also be applied more widely in other protein‐protein interfaces to create increasingly more artificial proteins for various biomedical applications.
It
is generally believed that a protein’s sequence solely
determines its native structure, but how the long- and short-range
interactions jointly determine the native structure/conformation of
the protein or every local fragment of the protein is still not fully
understood. Since most protein fragments are unstructured on their
own, direct observation of the folding of flexible protein fragments
is very difficult. Interestingly, we show that it is possible to graft
the complementary-determining regions (CDRs) of antibodies onto the
surface of a gold nanoparticle (AuNP) to create AuNP-based artificial
antibodies (denoted as Goldbodies), such as an antilysozyme Goldbody.
Goldbodies can specifically recognize the corresponding antigens like
the original natural antibodies do, but direct structural evidence
for the refolding or restoration of native conformation of the grafted
CDRs on AuNPs is still missing and in high demand. Herein we design
a new Goldbody that targets an epitope on the lysozyme different from
that of the previous antilysozyme Goldbody, and the one circle of
helix in the CDR makes it possible to distinguish the unfolded conformation
of the free CDR and its folded conformation on AuNPs by circular dichroism
(CD) spectroscopy. The refolding of flexible protein fragments on
NPs provides unique evidence and inspiration for understanding the
fundamental principles of protein folding.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.